|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NAT8 |
Gene summary for NAT8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NAT8 | Gene ID | 9027 |
| Gene name | N-acetyltransferase 8 (putative) | |
| Gene Alias | ATase2 | |
| Cytomap | 2p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9UHE5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9027 | NAT8 | HCC1_Meng | Human | Liver | HCC | 4.78e-84 | 4.05e-01 | 0.0246 |
| 9027 | NAT8 | Pt14.a | Human | Liver | HCC | 1.53e-05 | 3.41e-01 | 0.0169 |
| 9027 | NAT8 | S014 | Human | Liver | HCC | 1.87e-02 | 2.25e-01 | 0.2254 |
| 9027 | NAT8 | S015 | Human | Liver | HCC | 9.28e-07 | 7.09e-01 | 0.2375 |
| 9027 | NAT8 | S016 | Human | Liver | HCC | 1.69e-03 | 2.70e-01 | 0.2243 |
| 9027 | NAT8 | S027 | Human | Liver | HCC | 6.63e-17 | 1.16e+00 | 0.2446 |
| 9027 | NAT8 | S028 | Human | Liver | HCC | 9.87e-39 | 1.48e+00 | 0.2503 |
| 9027 | NAT8 | S029 | Human | Liver | HCC | 6.57e-44 | 1.74e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
| GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
| GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
| GO:000657521 | Liver | HCC | cellular modified amino acid metabolic process | 119/7958 | 188/18723 | 6.47e-09 | 1.67e-07 | 119 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:000674911 | Liver | HCC | glutathione metabolic process | 44/7958 | 64/18723 | 1.95e-05 | 2.09e-04 | 44 |
| GO:199000011 | Liver | HCC | amyloid fibril formation | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0048022 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
| hsa0048032 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NAT8 | SNV | Missense_Mutation | c.82N>A | p.His28Asn | p.H28N | Q9UHE5 | protein_coding | tolerated(0.09) | benign(0.025) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
| NAT8 | SNV | Missense_Mutation | novel | c.584N>C | p.Lys195Thr | p.K195T | Q9UHE5 | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NAT8 | insertion | In_Frame_Ins | novel | c.126_127insTTGTGGGGT | p.Leu43_Ile44insTrpGlyLeu | p.L43_I44insWGL | Q9UHE5 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NAT8 | insertion | Frame_Shift_Ins | novel | c.125_126insATCTGAGTCCCATGTGATTG | p.Leu43SerfsTer27 | p.L43Sfs*27 | Q9UHE5 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NAT8 | SNV | Missense_Mutation | c.13C>G | p.His5Asp | p.H5D | Q9UHE5 | protein_coding | deleterious(0) | possibly_damaging(0.758) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAT8 | SNV | Missense_Mutation | c.7N>T | p.Pro3Ser | p.P3S | Q9UHE5 | protein_coding | tolerated(0.27) | benign(0.343) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NAT8 | SNV | Missense_Mutation | rs754121016 | c.86N>T | p.Ala29Val | p.A29V | Q9UHE5 | protein_coding | tolerated(0.79) | benign(0) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NAT8 | SNV | Missense_Mutation | c.370N>T | p.Ala124Ser | p.A124S | Q9UHE5 | protein_coding | deleterious(0.02) | possibly_damaging(0.544) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| NAT8 | SNV | Missense_Mutation | c.317N>A | p.Gly106Asp | p.G106D | Q9UHE5 | protein_coding | tolerated(0.21) | benign(0.194) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NAT8 | SNV | Missense_Mutation | rs555774069 | c.67N>T | p.Arg23Trp | p.R23W | Q9UHE5 | protein_coding | deleterious(0.04) | benign(0.394) | TCGA-DM-A1DB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |